Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3853747 | 0.99 | KMT2A (0.51) | HSD11B1KMT2ARXFP1PRNPLMNA | |
| SCHEMBL6772222 | 0.84 | KMT2A (0.51) | HSD11B1KMT2ALMNAMAPK1ALDH1A1 | |
| Bromide SCHEMBL3853944 | 0.76 | CNR2 (0.42) | HSD11B1KMT2ARXFP1PRNPLMNA | |
| SCHEMBL6766613 | 0.75 | SLC9A1 (0.47) | KMT2AMAPT | |
| Alagebrium SCHEMBL1820212 | 0.75 | KMT2A (0.71) | KMT2ALMNAMAPK1ALDH1A1MAPT | |
| SCHEMBL13963145 | 0.74 | HSD11B1 (0.62) | HSD11B1KMT2ARXFP1PRNPLMNA | |
| SCHEMBL4834908 | 0.74 | HSD11B1 (0.62) | HSD11B1KMT2ARXFP1PRNPLMNA | |
| Alagebrium SCHEMBL1648822 | 0.74 | KMT2A (0.74) | KMT2ALMNAMAPK1ALDH1A1MAPT | |
| Alagebrium SCHEMBL225618 | 0.74 | KMT2A (0.69) | KMT2ALMNAMAPK1ALDH1A1MAPT | |
| SCHEMBL2099000 | 0.73 | HSD11B1 (0.61) | HSD11B1KMT2ARXFP1PRNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1128830-B1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | SYNVISTA THERAPEUTICS INC (US) | 2008-03-12 | — | — | EP | claimed |
| US-6790859-B2 | THERAPY OR REDUCING PROGRESSION OF HYPERTENSION OR DAMAGE TO A TISSUE CAUSED BY CONTACT WITH ELEVATED LEVELS OF REDUCING SUGARS IN AN ANIMAL, COMPRISING ADMINISTERING TO THE ANIMAL AN EFFECTIVE AMOUNT OF THIAZOLIUM COMPOUNDS | ALTEON INCORPORATED | 2004-09-14 | — | — | US | claimed |
| EP-1128830-A4 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | ALTEON INC (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | SYNVISTA THERAPEUTICS, INC. | 2003-09-18 | — | — | US | claimed |
| JP-2002529414-A | — | — | 2002-09-10 | — | — | JP | claimed |
| US-6319934-B1 | TREATING STIFFENING OF BLOOD VASCULATURE, ATHEROSCLEROSIS, RETINOPATHY, CATARACTS, PERIPHERAL NEUROPATHY OR OSTEOARTHRITIS IN AN ANIMAL | ALTEON, INC. | 2001-11-20 | — | — | US | claimed |
| EP-1128830-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | Alteon, Inc. (US) | 2001-09-05 | — | — | EP | claimed |
| US-6121300-A | IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES | SYNVISTA THERAPEUTICS, INC. | 2000-09-19 | — | — | US | claimed |
| WO-2000027395-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | ALTEON, INC. (US) | 2000-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | AGER, OGA, PTMS | HSD11B1 4477/4885KMT2A 2454/4885RXFP1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.